Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Limited has announced a significant change in the holdings of their Director, Dr. Christopher Burns, who acquired 616,672 ordinary shares through an entitlement offer at $0.055 each. The company is known for its focus on developing Focal Adhesion Kinase inhibitors for cancer and fibrotic diseases, including pancreatic cancer and idiopathic pulmonary fibrosis. This move could indicate increased internal confidence in Amplia’s future prospects.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
